Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Hammond, Jennifer, Leister-Tebbe, Heidi, Gardner, Annie, Abreu, Paula, Bao, Weihang, Wisemandle, Wayne, Baniecki, MaryLynn, Hendrick, Victoria M., Damle, Bharat, Simón-Campos, Abraham, Pypstra, Rienk, Rusnak, James M.·2022·New England Journal of Medicine
DOI 10.1056/nejmoa2118542

Cited by (1,002)

Items 1,001–1,002 of 1,002

  1. Oral antivirals for COVID-19 among patients with cancer
    Dorra Guermazi, Panos Arvanitis, Kendra Vieira, Jeremy Lyle Warner, Dimitrios Farmakiotis · 2024 · Supportive Care in Cancer
  2. Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19
    Schilling, William HK, Jittamala, Podjanee, Watson, James A, Ekkapongpisit, Maneerat, Siripoon, Tanaya, Ngamprasertchai, Thundon, Luvira, Viravarn, Pongwilai, Sasithon, Cruz, Cintia, Callery, James J et al. · 2022